Proteomics, Genomics & Microarrays


High Performance Microplates Enhance Cell Growth and Survival


The Sero Krystal™ PDL range of coated microplates from Porvair Sciences set a new benchmark for reproducible cell culture even with challenging cell types.


Many scientists would prefer to grow cells in a serum-free environment to more accurately mimic physiological conditions. However, this often presents challenges as cell lines often struggle to attach to traditional tissue culture plastics in the absence of serum. Manufactured from ultra- pure polystyrene in a clean room environment, Sero Krystal™ Poly-D-Lysine (PDL) coated microplates were developed by Porvair Sciences to overcome these challenges and promote superior cell attachment, growth and proliferation for a wide range of cell types in serum-free media.


Poly-D-Lysine is a synthetic (animal-free) extracellular matrix used in cell culture applications to promote cell adhesion. Available in 96- and 384-well formats these new Sero Krystal™ PDL microplates are uniformly coated with a 70 to 150 kDa PDL polymer using proprietary methods. The coating creates a uniform net positive charge on the surface of the plate wells. This positive surface charge improves electrostatic interactions between the coated surface and the negative charges of the cell membrane resulting in improved cell attachment. Sero Krystal™ microplates are ideal for the culture of transfected cell lines, primary neurons, glial cells and fibroblasts, such as the adherent mouse fibroblast cell line L929 and other common adherent cell lines including HEK-293, BHK-21, PC12 and, NSC-34.


Available in clear, black and frame versions - Sero Krystal™ PDL coated microplates incorporate an optically clear base. The consistent flatness of the Sero Krystal™ microplate base gives superior light transmission for high resolution imaging and a flat optical plane for growing cells.


Supplied sterile and ready-to-use, Sero Krystal™ PDL coated microplates are the first part of the new Sero™ range of cell culture plates to launch from Porvair Sciences. More information online: ilmt.co/PL/kmZm


57687pr@reply-direct.com


Aptamers for Cancer Diagnosis and Therapy


There are two major applications for aptamers in cancer therapy. Aptamers can be used as antagonists by targeting and inhibiting cancer- specific molecules. They can also be used as delivery vehicles for therapeutics by specifically targeting cell membrane receptors on cancer cells. In this application, aptamer-drug conjugates bind to and are internalised by cancer cells while avoiding damage to healthy cells.


AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer. Aptamers bind to target molecules with the same affinity and specificity as antibodies but offer significant advantages, in particular a lack of immunogenicity, which makes them an ideal tool for cancer diagnosis and therapy.


Aptamers also have enormous potential for use in cancer diagnostics. They can be used to identify cancer cells and recognise cancer biomarkers, cancer metabolites and differentiating cells as well as molecules that affect tumour behaviour. New aptamer-based technologies such as cell-SLEX are increasingly being used to screen for aptamers that bind to cancer cell-surface protein biomarkers as they overcome the traditional shortfalls of mass spectrometry and antibody-based methods - cross-reactivity, poor reproducibility, complexity, and high cost.


More information online: ilmt.co/PL/lBlk 57965pr@reply-direct.com


Cas9 Protein for Clinical Genome Editing Research


A new GMP-manufactured Gibco CTS TrueCut Cas9 Protein has been launched by Thermo Fisher Scientific. TrueCut Cas9 proteins are manufactured with United States Pharmacopeia standards in mind, including traceability documentation, aseptic manufacturing and safety testing.


Providing consistent high-editing efficiency in all tested cell lines and greater than 90% efficiency in human primary T-cells, Gibco CTS TrueCut Cas9 Protein is a compelling solution for CAR T-cell therapy research using CRISPR-Cas9 genome editing. With the addition of a GMP- manufactured Cas9 protein and the recently launched Gibco CTS Xenon Electroporation System, Thermo Fisher can now support researchers across the autologous T-cell workflow.


“As genome editing quality and regulatory requirements continue to evolve, we are focused on providing solutions to meet scientists’ needs as they transition from the bench to the clinic,” said Brandon Pence, Vice President and General Manager of Cell Biology at Thermo Fisher Scientific. “By adding the Gibco CTS TrueCut Cas9 Protein to our portfolio of genome editing solutions, we can now support scientists in their journey to develop personalised CAR T-cell therapeutics.”


The Gibco CTS TrueCut Cas9 Protein is part of Thermo Fisher’s Cell Therapy Systems (CTS) product line, a comprehensive portfolio of GMP- manufactured products supported by traceability documentation. This product line is designed to work synergistically across the entire workflow, from cell isolation/activation to cell engineering and expansion, to address cell therapy developers’ manufacturing needs.


More information online: ilmt.co/PL/4zXl 57821pr@reply-direct.com


The Spotlight could be on you! Check out our Media Information Pack for further details and send your Press Releases to pr@intlabmate.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56